Cancer drug may reduce symptoms of severe COVID-19
In patients with COVID-19, off-label use of a cancer drug reduced respiratory distress and over-reactive immune responses. The results were used to inform the design of a clinical trial.
Source: NIH Research Matters from the National Institutes of Health (NIH) - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | COVID-19 | Health | National Institutes of Health (NIH) | Respiratory Medicine